Physician profile
Mitchell L Barrett
NPI 1952553869
$2,316.54
in general payments reported to CMS, 2019-2025
15 companies · $748 in 2025
The $748 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $290 · 2023: $526 · 2024: $310 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $438.70 | 2023-2025 | Auvelity, Symbravo |
| Abbvie INC. | $377.88 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $220.82 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $200.20 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $197.36 | 2025 | Jornay Pm |
| Corcept Therapeutics | $178.02 | 2022-2023 | Korlym |
| Novo Nordisk INC | $124.95 | 2023 | Wegovy |
| Mayne Pharma Commercial LLC | $122.59 | 2023 | |
| Idorsia Pharmaceuticals US INC | $115.47 | 2023 | Quviviq |
| Lilly USA, LLC | $96.28 | 2022 | |
| Coloplast Corp | $75.16 | 2021 | |
| Boston Scientific Corporation | $70.89 | 2021 | |
| Vanda Pharmaceuticals INC. | $43.11 | 2024 | Fanapt, Hetlioz |
| Antares Pharma, INC. | $38.11 | 2024-2025 | Xyosted |
| Tolmar, INC. | $17.00 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.